IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Haddad, Maher M.
Avi ASHKENAZI, et al.	Group Art Unit: 1644
Application Serial No. 10/767,374	Confirmation No. 4761
Filed: January 29, 2004	Attorney's Docket No. 39780-1216 R1C1D1
For: **COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY A-33 RELATED ANTIGENS**	**Customer No. 35489**

DECLARATION OF MENNO VAN LOOKEREN CAMPAGNE, Ph.D. UNDER 37 C.F.R. § 1.132

I, Menno van Lookeren, Ph.D., declare and say as follows:

1. I obtained a masters degree in neuropharmacology from the State University of Utrecht, Utrecht, the Netherlands in 1987. In 1991, I was awarded a Ph.D. at the Rudolf Magnus Institute of Pharmacology, State University of Utrecht, Utrecht, the Netherlands.

2. Between 1991 and 1997 I worked as a post-doctoral fellow, first at the Netherlands Institute of Brain Research, Amsterdam, the Netherlands, and later at Hoffmann-La Roche, Department of Neuroscience, Basel, Switzerland. From 1997 to 1999 I was employed as a visiting scientist at the Department of Cardiovascular Research of Genentech, Inc., South San Francisco, CA. I am currently a scientist at the Department of Immunology of Genentech, Inc.

3. My Curriculum Vitae, including a list of my publications, is attached to and forms part of this Declaration (Exhibit A).

4. My current responsibilities include strategic leadership for initiation and advancement of discovery programs in immunology. As part of these responsibilities, I am responsible for the identification and functional characterization of novel molecules expressed on

myeloid cells and for developing therapeutic entities for the treatment of inflammatory and autoimmune diseases.

5. Experiments to test the PRO362 polypeptide in mouse models of collagen-induced arthritis (CIA) and antibody-mediated arthritis were conducted in my laboratory, either personally by me or under my supervision.

6. For use in such experiments, a murine PRO362-Ig fusion protein was generated by fusing the hinge, CH2 and CH3 domains of murine IgG1 to the extra cellular domain (aa 1-200) of murine PRO362 (muPRO362), the polypeptide sequence of which is shown in Exhibit B. murine PRO362 shows about 67% overall sequence identity to human PRO362, with about 83% identity residing in the extracellular domain. A fusion containing a double mutation preventing Fc receptor binding was used to control for Fc receptor regulation. The nucleotide sequence of the muPRO62-Fc fusion protein is shown as Exhibit C. Protein was produced in CHO cells by transient transfections of plasmid DNA. The fusion protein was purified by running the cell supernatant over a protein A column followed by ion-exchange chromatography to eliminate aggregates. Serum half life was estimated by injecting a single dose of 4 mg/kg muPRO362-Fc in a C57B6 mouse followed by obtaining serum from the mice at specified time intervals. The serum levels of muPRO362-Fc was determined by a sandwich ELISA using to anti-muPRO362 monoclonal antibodies recognizing different epitopes on the extracellular domain of muPRO362.

7. In the collagen-induced arthritis (CIA) model, 70 DBA-1J 7 to mice (7 to 8 weeks old, Jackson Laboratories) were divided into 5 treatment groups, two groups (G1 and G3) with 15 mice per group, two groups (G4 and G5) with 10 mice per group, and one group (G2) with 20 mice.

G1: MuIgG1 isotype 4 mg/kg in 100 µl saline, s.c., 3-times per week for 7 weeks (n=15).

G2 : MuPRO362-IgG1 4 mg/kg in 100 µl saline, s.c., 3-times per week for 7 weeks (n=20).

G3: MuTNFRII-IgG1 isotype 4 mg/kg in 100 µl saline, s.c., 3-times per week for 7 weeks (n=15).

G4: MuIgG1 isotype 4 mg/kg in 100 µl saline, s.c., 3-times per week for 7 weeks, anaesthesia with in vivo microCT (n=10).

G5: MuTNFRII-IgG1 1.0 mg/kg in 100 µl saline, s.c., 3-times per week for 7 weeks, anesthesia with *in vivo* microCT (n=10).

TNF is a cytokine secreted by mononuclear phagocytes, Ag-stimulated T cells, NK cells and mast cells. It is involved in normal inflammatory and immune responses. TNF-α plays an important role in the pathogenesis of rheumatoid arthritis (RA). Elevated levels of TNF were found in synovial fluid of RA patients. In this protocol, mTNFRII-Fc was used as a positive control, to block the interaction between TNF and its cell surface receptors.

All mice from G1 to G5 were immunized with 100 µg bovine collagen type II in 100 µl Complete Freund's Adjuvant (CFA) on day). The collagen type II in CFA was injected intradermally at the base of the tail on the right side. At day 21, a second immunization with 100 µg bovine collagen type II in 100 µl of incomplete Freund's Adjuvant was given intradermally at the left side of the tail.

Animals were checked daily. Mice in the G4-5 groups were anesthesized with isoflurane and in vivo microCt was performed weekly. Terminal faxitron X-Rays and microCT were taken at the end of study, ad joint lesion/erosion was evaluated.

On day 35 and at the termination of the study, mice in groups G1-5 were bled fro serum pK and anti-collagen type II antibody titer (100 µl orbital bleed). On day 70 all mice were terminally bled intracardiac under 3% isoflurane for terminal hemogram and differential leukocyte count and serum for pK (G3).

The mice were euthanized at day 70 post induction of arthritis. All four limbs were collected for radiographs, microCT and histopathology.

Figure 1 (Exhibit D) shows significant reduction in joint swelling in muPRO362-Fc treated mice.

Immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue (H&E staining), obtained from muPRO362-Fc treated animals at day 70, shows inhibition of joint inflammation as a result of treatment. Figure 2 (Exhibit E) shows H&E stained sections of a meta-tarsal joint of a DBA1/J mouse 70 days after immunization with collagen type II. A. Massive inflammatory cell infiltrate is found in the areas surrounding tendon sheats and the area surrounding the joint cavity; B. Detail of A; C. Low degree of inflammatory infiltrate in the joint

of a mouse treated with muPRO362-Fc. Few inflammatory cells were found in the areas surrounding the tendon sheats and the joint cavity; D.

Figure 3 (Exhibit F) shows that cortical bone volume was preserved in joints of mice treated with muPRO362-Fc. Mice in control IgG- and muPRO362-Fc-treated groups were sacrificed 70 days after collagen injection, and joints were scanned by μCT. Bone erosion and loss of bone density in joints of mice representative of muPRO362-Fc and control IgG groups are shown in the left figure as compared to muIgG1 treated animals. Preservation of cortical bone volume was significantly greater in muPRO362-Fc treated animals. The images are a three-dimensional surface rendering created from the μCT data using Analyze image analysis software.

Figure 4 (Exhibit G) shows that muPRO362-Fc treatment does not alter the number nor the morphology of tissue resident macrophages. Livers and lungs from mice treated with either anti-gp120 IgG1 (left figures) or muPRO362-Fc (right figures) were dissected, fixed in formalin and embedded in paraffin wax. Seven micron sections were stained using an antibody to F4/80. Careful examination of the sections shows equal numbers of F4/80 positive macrophages in both treatment groups. In addition, there were no differences observed in the morphology of the macrophages

Figure 5 (Exhibit H) shows that muPRO362-Fc treatment does not affect serum anti-collagen antibody titers. Serum titers of anti collagen antibodies were determined 70 days following immunization. No differences were found in the serum titers of IgG1, IgG2a and IgM subclasses of antibodies in muPRO362-Fc treated versus anti gp120 treated animals. This means that muPO362-Fc does not affect antibody responses in mice immunized with collagen type II.

Figure 6 (Exhibit I) shows that muPRO362-Fc decreases the number of circulating inflammatory macrophages. Peripheral blood was obtained from muPRO362-Fc and anti gp-120 treated animals 70 days after immunization and analysed by flow cytometry using markers for inflammatory and non-inflammatory monocytes. MuPRO362-Fc treated animals showed a significant increase in the number of inflammatory monocytes and a decrease in the number of non-inflammatory monocytes as compared to the anti gp120 treated group.

The results of these experiments demonstrate that the muPRO362-Fc fusion protein inhibits collagen-induced arthritis. In particular, the results show that muPRO362-Fc inhibits

joint swelling, inhibits inflammation, preserves cortical joint bone volume, and decreases the number of circulating inflammatory macrophages.

7. PRO362-Fc fusion proteins were also tested in a mouse model of antibody-mediated arthritis.

Antibody-mediated arthritis can be induced by i.v. injection of a combination of four different monoclonal antibodies generated by the Arthrogen-CIA® mouse B-hybridoma cell lines (Terato et al., J. Immunol. 148:2103-8 (1992)). Three of the monoclonal antibodies recognize autoantigenic epitopes clustered within an 84 amino acid residue fragment, LyC2 (the smallest arthritogenic fragment of type II collagen) of CB11 and the fourth monoclonal antibody reacts with LyC1. All four antibodies recognize the conserved epitopes shared by various species of type II collagen and cross-react with homologous and heterologous type II collagen (Terato et al., supra; Terato et al., Autoimmunity 22:137-47 (1995)). The Arthrogen-CIA® arthritis inducing monoclonal antibody cocktail is commercially available (Chemicon International, Inc., Temecula, CA, catalog No. 90035).

In these experiments, 10 BALB-c mice(CR/Hollister) of 4-5 weeks, were divide into two groups, with 5 mice in each group.

Animals were treated daily with 100 µg muPRO362-Fc or 100 µg control-Fc (anti-gp120 IgG1), starting the day prior to the injection of the antibody cocktail (day -1), and continuing until day 14. Animals were checked at least two-times per day, and written records of observations were kept. The extent of disease was scored by visual observation.

Visual scoring system:

0 = No evidence of erythema and swelling

1 = Erythema and mild swelling confined to the mid-foot

2 = Erythema and mild swelling extending from the ankle to the mid-foot

3 = Erythema and moderate swelling extending from the ankle to the metatarsal joints

4 = Erythema and severe swelling encompass the ankle, foot and digits

Nestlets were used as an enrichment device and to provide extra padding for the animals. All animals were sacrificed on day 14, and joints were harvested for immunohistochemical staining or haematoxylin-eosin staining. Blood was sampled for hematological analysis.

Figure 7 (Exhibit J) shows macrophage infiltration in joints following antibody-induced arthritis (AIA), generated with F4/80 staining in undecalcified frozen joints. Female Balb/C mice were injected with 2 mg of anti collagen antibodies (arthrogen) i.v. followed 3 days later by injection with 25 ug LPS i.p. 14 days following antibody injection, mice were euthanized and the paws were collected, and embedded in polyvinyl alcohol. 7 μm thick sections were cut from the frozen joints and stained with antibodies to muPRO362 and to F4/80, a macrophage specific marker.

Figure 8 (Exhibit K) demonstrates that muPRO362 prevents joint swelling following antibody-induced arthritis in Balb/c mice. Arthritis was induced by the method of Terato and colleagues (Terato et al., (1992), supra; Terato et al., (1995) supra) using a mixture of 4 monoclonal antibodies recognizing a conserved epitope on callegn type II (Chemicon). Female Balb/C mice, 6 weeks old, were injected i.v. with 2 mg anti CII antibody followed 3 days later with an i.p. injection of 25 μg LPS. Animals were treated daily either with murine PRO362-Fc fusion protein or with a control-Fc fusion protein. Dosing was 4 mg/kg in 100 μl PBS subcutaneous. Treatment started the day prior to anti collagen antibody injection and continued until them ice were euthanized at day 14. Mice were observed daily post LPS injection for swelling of the hind paw as a sign of arthritis. The severety of arthritis was graded on a 1-16 scale as follows: 0 = No evidence of erythema and swelling, 1 = Erythema and mild swelling confined to the mid-foot (tarsal) or ankle, 2 = Erythema and mild swelling extending from the ankle to the mid-foot, 3 = Erythema and moderate swelling extending from the ankle to the metatarsal joints, 4 = Erythema and severe swelling encompass the ankle, foot and digits.

Therapeutic treatment was performed similar to prophylactic treatment apart from the treatment start which was at day 4 rather than day -1. muPRO362-Fc treatment reduced levels of inflammatory cytokines in paws of AIA mice. Measurement of cytokine, C3a and C5a concentration in arthritic hindpaw performed according to the method of Kagari et al, J. Immunol. 169:1459-66 (2002). In short, at the indicated time points following the induction of antibody-induced arthritis, paws were collected and frozen in liquid nitrogen. Subsequently, paws were pulverized on a liquid nitrogen-cooled metal plate and dispersed in ice-cold PBS containing 0.1% PMSF (Sigma). The samples were homogenized with a Vitatron (NL) homogenizer on ice, insoluble parts were removed by spinning at 14000 g for 10 min and

collection of supernatant. Cytokines in the supernatant were measure using cytokine ELISA's from BD Pharmingen.

muPRO362-Fc treatment inhibits deposition of complement C3 but not of IgG2a on cartilage in AIA. Female Balb/C mice were injected with 2 mg of anti collagen antibodies (arthrogen) i.v. followed 3 days later by injection with 25 ug LPS i.p. 14 days following antibody injection, mice were euthanized and the paws were collected, embedded in polyvinyl alcohol and frozen in ispenthane cooled on dry iced. 7 um thick sections were cut from the frozen joints and stained with a FITC-coupled polyclonal antibody to murine C3 (Calbiochem) and a polyclonal A594-coupled antibody to murine IgG2a (Jackson Immunoresearch). Sections were photographed in a Leitz fluorescent microcope

The results of immunohistochemistry performed with H&E staining are shown in Figure 9 (Exhibit L). Control-treated mice (muIgG1) had moderate to severe arthritis (left panel), muPRO362-treated mice has minimal to no arthritis (right panel). The results show that muPRO362 inhibits joint inflammation in antibody-induced arthritis.

In conclusion, animals treated with muPRO362-Fc had significantly reduced clinical scores as compared to animals treated with anti-gp120 IgG1. PRO362 demonstrated both prophylactic and therapeutic efficacy in this animal model. The decrease in severity of arthritis was also reflected by a decrease in inflammatory cells, especially neutrophils, in the joints. There was an increased number of neutrophils in the circulation possibly reflecting a decrease in neutrophil migration into the joint. muPRO362-Fc inhibited local IL-1β and IL-6 production in parallel with clinical manifestation of RA. muPRO362 treatment did not affect immune complex deposition, but inhibited complement C3 deposition on cartilage. The effector function was found to be independent of Fc receptor binding. huPRO362-short-Fc has also demonstrated significant prophylactic activity.

9. Both the collagen-induced arthritis (CIA) and the antibody-mediated arthritis models have been used my many laboratories to test drug candidates for the treatment of human rheumatoid arthritis. The histopathology of CIA resembles those seen in RA with synovial proliferation that progresses to pannus formation, cartilage degeneration/destruction and marginal bone erosions with subsequent joint deformities. Antibody-mediated arthritis differs from CIA in that instead of injecting the antigen (bovine collagen type II), antibodies

recognizing type II collagen are injected. In this way, adaptive B and T cell responses are circumvented to directly induce effector functions on macrophages and neutrophils through Fc receptor and complement-mediated activation. Based on the experimental findings in these two well known and recognized animal models, described in paragraphs 7 and 8 above, it is my considered scientific opinion that PRO362, a novel macrophage associated receptor with homology to A33 antigen and JAM1, is a promising drug candidate for the treatment of rheumatoid arthritis. In addition, based on these experimental data, including the demonstrated ability of PRO362 to reduce the level of inflammatory cytokines, and my knowledge of the relevant art, it is my considered scientific opinion that PRO362 has anti-inflammatory properties, which are expected to lead to the development of therapeutic approaches for the treatment other inflammatory diseases or conditions as well.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Menno van Lookeren Campagne, Ph.D.

03.14.06
Date

Menno van Lookeren Campagne

Department of Immunology
Genentech, Inc.
1 DNA Way, South San Francisco, CA 94080
Phone: (650) 225-1755
Fax (650) 225-8221
Email: menno@gene.com

Employment and Education

1999 - present:	**Scientist**, Department of Immunology, Genentech Inc., South San Francisco, California, U.S.A.
1997 - 1999:	**Visiting Scientist**, Department of Cardiovascular Research, Genentech Inc., South San Francisco, California, U.S.A.
1994 -1997:	**Post-Doctoral Fellow**, Hoffmann-la Roche, Department of Neuroscience, Basel, Switzerland.
1991-1994:	**Post-Doctoral Fellow**, Netherlands Institute of Brain Research, Amsterdam, Netherlands.
1987-1991:	**Ph.D.** Rudolf Magnus Institute of Pharmacology, State University of Utrecht, Netherlands.
1979-1987:	**Masters** degree in neuropharmacology, State University of Utrecht, Utrecht, Netherlands.

Research Experience

1999 - present: Genentech Inc.: Provide strategic leadership for initiation and advancement of discovery programs in immunology. Responsible for the identification and functional characterization of novel molecules expressed on myeloid cells and responsible for developing therapeutic entities that target these molecules in inflammatory- and autoimmune diseases. *Reporting to Dr. Andy C. Chan and Dr. Flavius Martin.*

1997 - 1999: Genentech Inc.: Studied the molecular mechanisms of delayed neuronal death in a model of mild focal cerebral ischemia. Combined magnetic resonance imaging with novel molecular biology tools to correlate the time course of delayed neuronal death with the transcriptional activation and expression of genes involved in DNA repair and anti-oxidant activities. Supervised the development of a model of mild focal ischemia in the mouse. Knock-out and transgenic approaches have been applied to study the role of key anti-oxidant and metal-detoxifying proteins in protecting against ischemic neuronal cell death in mouse models. *Advisors: Dr. G. Roger Thomas and Dr. David G. Lowe.*

1994 -1997: Hoffmann-la Roche: Studied the role of pro-apoptotic and anti-apoptotic gene expression in delayed cell death following global and focal cerebral ischemia using biochemical, molecular biological and immunohistochemical approaches. Compared the gene expression pattern in neurons following cerebral ischemia with that in neurons undergoing apoptotic cell death during development. *Advisor: Dr. Ramanjit Gill.*

1991-1994: Netherlands Institute of Brain Research: Performed studies on the physiology and pathophysiology of excitatory amino acids and their antagonists in the developing rat brain. These studies were performed to obtain a better understanding of the mechanisms and possible treatment strategies of neonatal asphyxia/ischemia. Magnetic resonance imaging and electrophysiology were

applied to detect early cellular pathology following injection of excitatory amino acids. Receptor-ligand binding essays were performed to study conformational changes in excitatory amino acid receptors during normal development and following blockade of the receptors using specific antagonists. In addition, the induction of apoptosis by excitatory amino acids in the developing rat brain was directly addressed using several techniques including *in situ* end-labeling, DNA extraction and electron microscopy. *Advisors: Dr. Robert Balázs and Dr. Klaas Nicolay.*

1987-1991: University of Utrecht: Developed several new methods to localize neuronal proteins at the electron microscopic level. Used this approach to study the role of the growth-associated protein B-50/GAP-43 in neuronal survival, plasticity and differentiation in cell cultures and in the developing rat brain. *Thesis advisors: Prof. Dr. Willem-Hendrik Gispen and Prof. Dr. Arie J. Verkley.*

Research Interest

Identifying novel therapeutic targets for development of drugs to treat autoimmune and anti-inflammatory diseases.

Ad Hoc Reviewer and Referee

Journal of Neurocytology (1992)
Neuroreport (1993)
European Journal of Neuroscience (1993)
Journal of Cerebral Blood Flow and Metabolism (1998, 2000)
Brain Research (1998, 1999)
Microcirculation (2000)
Neurobiology of Ageing (2001)

Publications in Refereed Journals

Helmy, K.Y., Katschke, K.J., Gorgani, N.N., Kljavin, N.M., Elliott, J.M., Diehl, L., Scales, S.J., Ghilardi, N. and **van Lookeren Campagne, M.** (2006) *CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens.* Cell 124, 915-927..

Abbas, A. R., Baldwin, D., Ma, Y., Ouyang, W., Gurney, A., Martin, F., Fong, S., **van Lookeren Campagne, M.**, Godowski, P., Williams, P. M., *et al.* (2005). *Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data.* Genes Immun *6*, 319-331.

Valdez PA, Wang H, Seshasayee D, van **Lookeren Campagne M**, Gurney A, Lee WP, Grewal IS. *NTB-A, a new activating receptor in T cells that regulates autoimmune disease.* J Biol Chem. 279 (2004) 18662-18669

Van Lookeren Campagne, M., Thibodeaux, H., van Bruggen, N. and Lowe, D., *Increased binding activity at an antioxidant-responsive element in the metallothionein-1 promoter and rapid induction of metallothionein-1 and -2 in response to cerebral ischemia and reperfusion.* J. Neurosci. 20 (2000) 5200-5207.

Gerlai, R., Thibodeaux, H., Palmer, J.T., **Van Lookeren Campagne, M.**, van Bruggen, N. *Transient focal cerebral ischemia induces sensorimotor defects in mice.* Behav. Brain Res. 108 (2000) 63-71.

Van Bruggen, N., Thibodeaux, H., Palmer, JT, Cairns, B., Tumas, D., Gerlai, R., Williams, S.P., **Van Lookeren Campagne, M.,** Ferrara, N. *VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic/reperfusion injury in the mouse brain.* J. Clin. Inv. 104 (1999) 1613-1620.

Van Lookeren Campagne, M., Thibodeaux, H., Palmer, J.T, Williams, S.P., Gerlai, R., Cairns, B., van Bruggen, N. and Lowe, D. T., *Evidence for a protective role of metallothionein-1 in focal cerebral ischemia.* Proc. Natl. Acad. Sci. USA 96 (1999) 12870-12875.

Van Lookeren Campagne, M., Thibodeaux, H., Palmer, J.T., Williams, S.P., Thomas, R., Lowe, D. and van Bruggen, N. *Secondary reduction in the apparent diffusion coefficient, increase in cerebral blood volume and delayed neuronal death following middle cerebral artery occlusion and reperfusion in the rat.* J. Cereb. Blood Flow Metab. 19 (1999) 1354-1364.

Van Lookeren Campagne, M., Okamoto, K., Prives, C. and Gill, R. *Developmental expression and co-localization of cyclin G1 and the B' subunits of protein phosphatase 2A in neurons.* Mol Brain Res 64 (1999) 1 - 10.

Van Lookeren Campagne, M. and Gill, R. *Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: Comparison with expression of the cell cycle regulators* $p21^{Waf1/Cip1}$, $p27^{Kip1}$, $p57^{Kip2}$, $p16^{Ink4a}$, *cyclin G1 and the proto-oncogene Bax.* J. Comp. Neurol. 397 (1998) 181-198.

Van Lookeren Campagne, M. and Gill, R. *Increased expression of cyclin G1 and* $p21^{WAF1/CIP1}$ *following transient forebrain ischemia: Comparison with early DNA damage.* J Neurosci Res 53 (1998) 279-296.

Van Lookeren Campagne, M. and Gill, R. *Cell cycle-related gene expression in the adult rat brain: Selective induction of cyclin G and* $p21^{WAF1/CIP1}$ *in neurons following focal cerebral ischemia.* Neuroscience 84 (1998) 1097-1112.

Niendorf, Th., Dijkhuizen, R.M., Norris, D.G., **Van Lookeren Campagne, M.**, Nicolay, K. and Leibfritz, D., *Biexponential diffusion attenuation curves in various states of brain tissue: the implications for DWI.* Magn. Res. Med. 2 (1996) 412-418.

Dijkhuizen, R.M., **Van Lookeren Campagne**, M., Niendorf, T., Dreher, W., van der Toorn, A., Hoehn-Berlage, M., Verheul, H.B., Tulleken, C.A.F., Leibfritz, D., Hossmann, K.-A., Nicolay, K. *Status of the neonatal rat brain after NMDA-induced excitotoxic injury as measured by MRI, MRS and metabolic imaging.* NMR Biomed. 9 (1996) 84-92.

Van der Toorn, A., Syková, E., Dijkhuizen, R.M., Vorisek, I., Vargova, L., Skobisova, E., **Van Lookeren Campagne, M.**, Reese, T., and Nicolay, K. *Dynamic changes in water ADC, energy metabolism, extracellular space volume and tortuosity in neonatal rat brain during terminal anoxia.* Magn. Res. Med. 36 (1996) 52-60.

Van Lookeren Campagne, M. and Gill, R., *Ultrastructural morphological changes are not characteristic of apoptotic cell death following focal cerebral ischaemia in the rat.* Neurosci. Lett. 213 (1996) 111-114.

Lucassen, P.J., Chung, W.C.J., Vermeulen, J.P., **Van Lookeren Campagne**, J.P., Van Dierendonck, J.H. and Swaab, D.F., *Microwave enhanced in situ end-labelling of fragmented DNA; parametric studies in relation to post mortem delay and fixation of rat and human brain.* J Histochem. Cytochem. 43 (1995) 1163-1171.

Van Lookeren Campagne, M., Verheul, H.B., Vermeulen, J.P., Boer, G.J., Balázs, R. and Nicolay, K. *Developmental changes in NMDA-induced cell swelling and its transition to necrosis assessed with ^1H nuclear magnetic resonance imaging, impedance and histology.* Dev. Brain Res. 93 (1996) 109-119.

Chaudry, F.A., Lehre, K.P., **Van Lookeren Campagne, M.**, Ottersen, O.P., Danbolt, N.C. and Storm-Mathisen, J. *Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry.* Neuron 15 (1995) 711-720.

Van Lookeren Campagne, M., Vermeulen, J.P., Boer, G.J. and Balázs, R. *Treatment with NMDA receptor antagonists does not affect developmental changes in NMDA receptor properties in vivo.* Neurochem Int 27 (1995) 355-366.

Van Lookeren Campagne,M., Lucassen, P.J., Vermeulen, J.P. and Balázs, R. *NMDA and kainate induce internucleosomal DNA cleavage associated with both apoptotic and necrotic cell death in the neonatal rat brain.* Eur J. Neurosci. 7 (1995) 1627-1640.

Van Lookeren Campagne, M., Verheul, H.B., Nicolay, K. and Balázs, R. *Early evolution and recovery from excitotoxic injury in the neonatal rat brain: a study combining magnetic resonance imaging, electrical impedance and histology.* J Cereb. Blood Flow Metab. 14 (1994) 1011-1023.

Verheul, H.B., Balázs, R., Berkelbach van der Sprenkel, J.W., Tulleken, C.A.F., Nicolay, K. and **Van Lookeren Campagne, M.** *Comparison of diffusion-weighted MRI with changes in cell volume in a rat model of brain injury.* NMR Biomed. 6 (1994) 1-5.

Verheul, H.B., Balázs, R., Berkelbach van der Sprenkel, J.W., Tulleken, C.A.F., Nicolay, K. and **Van Lookeren Campagne**, M. *Temporal evolution of NMDA induced excitotoxicity in the neonatal rat brain as measured with ^1H nuclear magnetic resonance imaging.* Brain Res. 618 (1993), 203-212.

Van Lookeren Campagne, M. *Freeze-substitution as a tool for postembedding immunogold electron microscopy.* Neurosci. Prot. 1 (1993) 1-11.

Van Lookeren Campagne, M., Dotti, C.G., Verkleij, A.J., Gispen, W.H. and Oestreicher, A.B. *Redistribution of B-50/Growth associated protein 43 during differentiation and maturation of rat hippocampal neurons in vitro.* Neuroscience 51 (1992) 601-619.

Van Lookeren Campagne, M., Dotti, C.G., Jap Tjoen San, E.R.A., Verkleij, A.J., Gispen, W.H. and Oestreicher, A.B. *B-50/GAP43 localization in polarized hippocampal neurons in vitro: an ultrastructural quantitative study.* Neuroscience 50 (1992), 35-52.

Van Lookeren Campagne, M., Dotti, C.G., Verkleij, A.J., Gispen, W.H. and Oestreicher, A.B. *B-50/GAP43 localization on membranes of putative transport vesicles in the cell body, neurites and growth cones of cultured hippocampal neurons.* Neurosci. Lett. 137 (1992) 129-132.

Van Lookeren Campagne, M., Oestreicher, A.B., Van der Krift, T.P., Gispen, W.H. and Verkley, A.J. (1991) *Freeze substitution and Lowicryl HM20 embedding of fixed rat brain: suitability for the localization of neural antigens.* J Histochem. Cytochem. 39 (1992) 1267-1279.

Van Lookeren Campagne, M., Oestreicher, A.B., Buma, P., Verkleij, A.J. and Gispen, W.H. *Ultrastructural localization of adrenocorticotrope hormone (ACTH) immunoreactive fibers and the phosphoprotein B-50/GAP43 in the mesencephalic central gray substance of the rat.* Neuroscience 42 (1991) 517-529.

Van Lookeren Campagne, M., Oestreicher, A.B., Van der Krift, T.P., Gispen, W.H. and Verkley, A.J. *Immunogold ultrastructural localization of neural antigens in Lowicryl HM20 embedded, freeze substituted rat brain tissue.* Micron Microscopica Acta 21 (1990) 225-226.

Van Lookeren Campagne, M., Oestreicher, A.B., Van Bergen en Henegouwen, P.M.P. and Gispen, W.H. *Ultrastructural double localization of B-50/GAP43 and synaptophysin (p38) in neonatal and adult rat hippocampus.* J. Neurocytol. 19 (1990) 948-961.

Gorgels, T.G.M.F., **Van Lookeren Campagne, M.**, Oestreicher, A.B., Gribnau, A.A.M. and Gispen, W.H. *B-50/GAP43 is localized at the cytoplasmic side of the plasma membrane in developing and adult rat pyramidal tract.* J. Neurosci. 9 (1989) 3861-3869.

Van Lookeren Campagne, M., Oestreicher, A.B., Van Bergen en Henegouwen, P.M.P. and Gispen, W.H. *Ultrastructural immunocytochemical localization of B-50/GAP43, a protein kinase C substrate, in isolated presynaptic nerve terminals and neuronal growth cones.* J. Neurocytol. 18 (1989) 479-489.

Book Chapters and Editorial Comments

Lucassen, P.J., Labat-Moleur, F., Negoescu, A., and **Van Lookeren Campagne, M.**, *Microwave-enhanced om sotu end-labelling of apoptotic cells in tissue sections: Pitfalls and possibilities.* In: Antigen Retrieval Techniques, S-R Shi, J. Gu, C.R. Taylor (Eds.) Eaton Publishing (2000), Natick, MA

Van Bruggen, N. and **Van Lookeren Campagne, M.**, *Dynamics of cerebral tissue injury and perfusion after temporary hypoxia-ischemia in the rat.* Stroke 29 (1998) 704 (editorial comment)

Van Lookeren Campagne, M. and Gill, R. *DNA fragmentation associated with chromatin condensation is a late consequence of ischaemic cell death rather than a hallmark of apoptosis.* In: Pharmacology of Cerebral Ischemia, J. Kriegelstein (Ed.) Raven Press, New York (1996) pp. 77-83.

Van Lookeren Campagne, M., Oestreicher, A.B., De Graan , P.N.E. and Gispen, W.H. *Role of B-50/GAP43 in nerve growth cone function.* In: The Nerve Growth Cone, P.C. Letourneau, S.B. Kater and E.R. Macagno (Eds.), Raven Press, New York, pp. 97-109 (1992).

Awards

1993	Dutch Academy of Science Student Exchange Fellowship
1994	European Community Short Term Fellowship
1996	Aaron Diamond Post-doctoral Fellowship (declined)

Committee Member

University of Oslo, Insititute of Anatomy. Committee member and second opponent in examination for the degree of Doctor of Medicin, Erlend Nagelhus. Thesis: *Water and Volume Homeostasis in the Central Nervous System: Role of Glial Cells*, December 1998.

University of Kuopio, Finland. Committee member and first opponent in examination fro the degree of Doctor of Philosophy, Kaisa Kurkinen. Thesis: The role of PKCdelta in cerebral ischemia, December 2002.

Sequence 8

<210> 8
<211> 280
<212> PRT
<213> mus musculus

<400> 8

```
Met Glu Ile Ser Ser Gly Leu Leu Phe Leu Gly His Leu Ile Val Leu
 1               5                  10                  15
Thr Tyr Gly His Pro Thr Leu Lys Thr Pro Glu Ser Val Thr Gly Thr
            20                  25                  30
Trp Lys Gly Asp Val Lys Ile Gln Cys Ile Tyr Asp Pro Leu Arg Gly
        35                  40                  45
Tyr Arg Gln Val Leu Val Lys Trp Leu Val Arg His Gly Ser Asp Ser
    50                  55                  60
Val Thr Ile Phe Leu Arg Asp Ser Thr Gly Asp His Ile Gln Gln Ala
65                  70                  75                  80
Lys Tyr Arg Gly Arg Leu Lys Val Ser His Lys Val Pro Gly Asp Val
                85                  90                  95
Ser Leu Gln Ile Asn Thr Leu Gln Met Asp Asp Arg Asn His Tyr Thr
            100                 105                 110
Cys Glu Val Thr Trp Gln Thr Pro Asp Gly Asn Gln Val Ile Arg Asp
        115                 120                 125
Lys Ile Ile Glu Leu Arg Val Arg Lys Tyr Asn Pro Pro Arg Ile Asn
    130                 135                 140
Thr Glu Ala Pro Thr Thr Leu His Ser Ser Leu Glu Ala Thr Thr Ile
145                 150                 155                 160
Met Ser Ser Thr Ser Asp Leu Thr Thr Asn Gly Thr Gly Lys Leu Glu
                165                 170                 175
Glu Thr Ile Ala Gly Ser Gly Arg Asn Leu Pro Ile Phe Ala Ile Ile
            180                 185                 190
Phe Ile Ile Ser Leu Cys Cys Ile Val Ala Val Thr Ile Pro Tyr Ile
        195                 200                 205
Leu Phe Arg Cys Arg Thr Phe Gln Gln Glu Tyr Val Tyr Gly Val Ser
    210                 215                 220
Arg Val Phe Ala Arg Lys Thr Ser Asn Ser Glu Glu Thr Thr Arg Val
225                 230                 235                 240
Thr Thr Ile Ala Thr Asp Glu Pro Asp Ser Gln Ala Leu Ile Ser Asp
                245                 250                 255
Tyr Ser Asp Asp Pro Cys Leu Ser Gln Glu Tyr Gln Ile Thr Ile Arg
            260                 265                 270
Ser Thr Met Ser Ile Pro Ala Cys
        275                 280
```

Sequence 17

<210> 17
<211> 5988
<212> DNA
<213> homo sapiens

<400> 17
tcgagctcgc ccgacattga ttattgacta gttattaata gtaatcaatt acggggtcat 60
tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat ggcccgcctg 120
gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa 180
cgccaatagg gactttccat tgacgtcaat gggtggagta tttacggtaa actgcccact 240
tggcagtaca tcaagtgtat catatgccaa gtacgccccc tattgacgtc aatgacggta 300
aatggcccgc ctggcattat gcccagtaca tgaccttatg ggactttcct acttggcagt 360
acatctacgt attagtcatc gctattacca tggtgatgcg gttttggcag tacatcaatg 420
ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt gacgtcaatg 480
ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgccc 540
cattgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc agagctcgtt 600
tagtgaaccg tcagatcgcc tggagacgcc atccacgctg ttttgacctc catagaagac 660
accgggaccg atccagcctc cgcggccggg aacggtgcat tggaacgcgg attccccgtg 720
ccaagagtga cgtaagtacc gcctatagag tctataggcc cacccccttg gcttggccca 780
ccccttggc ttcgttagaa cgcggctaca attaatacat aaccttatgt atcatacaca 840
tacgatttag gtgacactat agaataacat ccactttgcc tttcacatcc actttgcctt 900
tctctccaca ggtgtccact cccaggtcca actgcacctc ggttctatcg attgaattcc 960
acgcgtccga gcagcaagag gatggaagga tgaatagaag tagcttcaaa taggatggag 1020
atctcatcag gcttgctgtt cctgggccac ctaatagtgc tcacctatgg ccaccccacc 1080
ctaaaaacac ctgagagtgt gacagggacc tggaaaggag atgtgaagat tcagtgcatc 1140
tatgatcccc tgagaggcta caggcaagtt ttggtgaaat ggctggtaag acacggctct 1200
gactccgtca ccatcttcct acgtgactcc actggagacc atatccagca ggcaaagtac 1260
agaggccgcc tgaaagtgag ccacaaagtt ccaggagatg tgtccctcca aataaatacc 1320
ctgcagatgg atgacaggaa tcactataca tgtgaggtca cctggcagac tcctgatgga 1380
aaccaagtaa taagagataa gatcattgag ctccgtgttc ggaaatataa tccacctaga 1440
atcaatactg aagcacctac aaccctgcac tcctctttgg aagcaacaac tataatgagt 1500
tcaacctctg acttgaccac taatgggact ggaaaacttg aggagaccat tgctggttca 1560
ggggggtca ccgacaagaa aattgtgccc agggattgtg gttgtaagcc ttgcatatgt 1620
acagtcccag aagtatcatc tgtcttcatc ttccccccaa agcccaagga tgtgctcacc 1680
attactctga ctcctaaggt cacgtgtgtt gtggtagaca tcagcaagga tgatcccgag 1740
gtccagttca gctggtttgt agatgatgtg gaggtgcaca cagctcagac gcaaccccgg 1800
gaggagcagt tcaacagcac tttccgctca gtcagtgaac ttcccatcat gcaccaggac 1860
tggctcaatg gcaaggagtt caaatgcagg gtcaacagtg cagctttccc tgcccccatc 1920
gagaaaacca tctccaaaac caaaggcaga ccgaaggctc cacaggtgta caccattcca 1980
cctcccaagg agcagatggc caaggataaa gtcagtctga cctgcatgat aacagacttc 2040
ttccctgaag acattactgt ggagtggcag tggaatgggc agccagcgga gaactacaag 2100
aacactcagc ccatcatgga cacagatggc tcttacttcg tctacagcaa gctcaatgtg 2160
cagaagagca actgggaggc aggaaatact ttcacctgct ctgtgttaca tgagggcctg 2220
cacaaccacc atactgagaa gagcctctcc cactctcctg gtaaatgagt cgacctgcag 2280
aagcttggcc gccatggccc aacttgttta ttgcagctta taatggttac aaataaagca 2340
atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt 2400
ccaaactcat caatgtatct tatcatgtct ggatcgggaa ttaattcggc gcagcaccat 2460
ggcctgaaat aacctctgaa agaggaactt ggttaggtac cttctgaggc ggaaagaacc 2520
agctgtggaa tgtgtgtcag ttagggtgtg gaaagtcccc aggctcccca gcaggcagaa 2580
gtatgcaaag catgcatctc aattagtcag caaccaggtg tggaaagtcc ccaggctccc 2640
cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccata gtcccgcccc 2700
taactccgcc catcccgccc ctaactccgc ccagttccgc ccattctccg ccccatggct 2760
gactaatttt ttttatttat gcagaggccg aggccgcctc ggcctctgag ctattccaga 2820
agtagtgagg aggcttttt ggaggcctag gcttttgcaa aaagctgtta acagcttggc 2880
actggccgtc gttttacaac gtcgtgactg ggaaaaccct ggcgttaccc aacttaatcg 2940
ccttgcagca catccccctt tcgccagctg gcgtaatagc gaagaggccc gcaccgatcg 3000
cccttcccaa cagttgcgca gcctgaatgg cgaatggcgc ctgatgcggt attttctcct 3060
tacgcatctg tgcggtattt cacaccgcat acgtcaaagc aaccatagta cgcgccctgt 3120
agcggcgcat taagcgcggc gggtgtggtg gttacgcgca gcgtgaccgc tacacttgcc 3180
agcgccctag cgcccgctcc tttcgctttc ttcccttcct ttctcgccac gttcgccggc 3240

Sequence 17

tttccccgtc aagctctaaa tcgggggctc cctttagggt tccgatttag tgctttacgg 3300
cacctcgacc ccaaaaaact tgatttgggt gatggttcac gtagtgggcc atcgccctga 3360
tagacggttt ttcgcccttt gacgttggag tccacgttct ttaatagtgg actcttgttc 3420
caaactggaa caacactcaa ccctatctcg ggctattctt ttgatttata agggattttg 3480
ccgatttcgg cctattggtt aaaaaatgag ctgatttaac aaaaatttaa cgcgaatttt 3540
aacaaaatat taacgtttac aatttttatgg tgcactctca gtacaatctg ctctgatgcc 3600
gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg acgggcttgt 3660
ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 3720
aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg gcctcgtgat acgcctattt 3780
ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttttcgggga 3840
aatgtgcgcg gaacccctat ttgtttattt ttctaaatac attcaaatat gtatccgctc 3900
atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 3960
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct 4020
cacccagaaa cgctggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt 4080
tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt 4140
tttccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtattgac 4200
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac 4260
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 4320
gccataacca tgagtgataa cactgcggcc aacttacttc tgacaacgat cggaggaccg 4380
aaggagctaa ccgcttttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 4440
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 4500
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa 4560
caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt 4620
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 4680
attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg 4740
agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt 4800
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt 4860
cattttaat ttaaaaggat ctaggtgaag atccttttttg ataatctcat gaccaaaatc 4920
ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaaagat caaaggatct 4980
tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta 5040
ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa ggtaactggc 5100
ttcagcagag cgcagatacc aaatactgtt cttctagtgt agccgtagtt aggccaccac 5160
ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct 5220
gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat 5280
aaggcgcagc ggtcgggctg aacgggggtt tcgtgcacac agcccagctt ggagcgaacg 5340
acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac gcttcccgaa 5400
gggagaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg 5460
gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg ccacctctga 5520
cttgagcgtc gatttttgtg atgctcgtca ggggggcgga gcctatggaa aaacgccagc 5580
aacgcggcct ttttacggtt cctggccttt tgctggcctt ttgctcacat gttctttcct 5640
gcgttatccc ctgattctgt ggataaccgt attaccgcct ttgagtgagc tgataccgct 5700
cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg aggaagcgga agagcgccca 5760
atacgcaaac cgcctctccc cgcgcgttgg ccgattcatt aatgcagctg gcacgacagg 5820
tttcccgact ggaaagcggg cagtgagcgc aacgcaatta atgtgagtta gctcactcat 5880
taggcacccc aggctttaca ctttatgctt ccggctcgta tgttgtgtgg aattgtgagc 5940
ggataacaat ttcacacagg aaacagctat gacatgatta cgaattaa 5988